288 related articles for article (PubMed ID: 29619607)
1. Pharmacokinetic/Pharmacodynamic Considerations of Beta-Lactam Antibiotics in Adult Critically Ill Patients.
Masich AM; Heavner MS; Gonzales JP; Claeys KC
Curr Infect Dis Rep; 2018 Apr; 20(5):9. PubMed ID: 29619607
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics, Pharmacodynamics, and Dosing Considerations of Novel β-Lactams and β-Lactam/β-Lactamase Inhibitors in Critically Ill Adult Patients: Focus on Obesity, Augmented Renal Clearance, Renal Replacement Therapies, and Extracorporeal Membrane Oxygenation.
Bakdach D; Elajez R; Bakdach AR; Awaisu A; De Pascale G; Ait Hssain A
J Clin Med; 2022 Nov; 11(23):. PubMed ID: 36498473
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics-pharmacodynamics issues relevant for the clinical use of beta-lactam antibiotics in critically ill patients.
Veiga RP; Paiva JA
Crit Care; 2018 Sep; 22(1):233. PubMed ID: 30244674
[TBL] [Abstract][Full Text] [Related]
4. Prolonged administration of β-lactam antibiotics - a comprehensive review and critical appraisal.
Osthoff M; Siegemund M; Balestra G; Abdul-Aziz MH; Roberts JA
Swiss Med Wkly; 2016; 146():w14368. PubMed ID: 27731492
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetic variability of beta-lactams in critically ill patients: A narrative review.
Boidin C; Moshiri P; Dahyot-Fizelier C; Goutelle S; Lefeuvre S
Anaesth Crit Care Pain Med; 2020 Feb; 39(1):87-109. PubMed ID: 31513935
[TBL] [Abstract][Full Text] [Related]
6. Beta-Lactam Infusion in Severe Sepsis (BLISS): a prospective, two-centre, open-labelled randomised controlled trial of continuous versus intermittent beta-lactam infusion in critically ill patients with severe sepsis.
Abdul-Aziz MH; Sulaiman H; Mat-Nor MB; Rai V; Wong KK; Hasan MS; Abd Rahman AN; Jamal JA; Wallis SC; Lipman J; Staatz CE; Roberts JA
Intensive Care Med; 2016 Oct; 42(10):1535-1545. PubMed ID: 26754759
[TBL] [Abstract][Full Text] [Related]
7. β-lactam pharmacokinetics and pharmacodynamics in critically ill patients and strategies for dose optimization: a structured review.
Sinnollareddy MG; Roberts MS; Lipman J; Roberts JA
Clin Exp Pharmacol Physiol; 2012 Jun; 39(6):489-96. PubMed ID: 22519600
[TBL] [Abstract][Full Text] [Related]
8. β-Lactam Therapeutic Drug Monitoring in Critically Ill Patients: Weighing the Challenges and Opportunities to Assess Clinical Value.
Dilworth TJ; Schulz LT; Micek ST; Kollef MH; Rose WE
Crit Care Explor; 2022 Jul; 4(7):e0726. PubMed ID: 35815181
[TBL] [Abstract][Full Text] [Related]
9. β-Lactam antimicrobial pharmacokinetics and target attainment in critically ill patients aged 1 day to 90 years: the ABDose study.
Lonsdale DO; Kipper K; Baker EH; Barker CIS; Oldfield I; Philips BJ; Johnston A; Rhodes A; Sharland M; Standing JF
J Antimicrob Chemother; 2020 Dec; 75(12):3625-3634. PubMed ID: 32989452
[TBL] [Abstract][Full Text] [Related]
10. Does Beta-lactam Pharmacokinetic Variability in Critically Ill Patients Justify Therapeutic Drug Monitoring? A Systematic Review.
Sime FB; Roberts MS; Peake SL; Lipman J; Roberts JA
Ann Intensive Care; 2012 Jul; 2(1):35. PubMed ID: 22839761
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetic/pharmacodynamic considerations for the optimization of antimicrobial delivery in the critically ill.
Tsai D; Lipman J; Roberts JA
Curr Opin Crit Care; 2015 Oct; 21(5):412-20. PubMed ID: 26348420
[TBL] [Abstract][Full Text] [Related]
12. Beta-Lactams Dosing in Critically Ill Patients with Gram-Negative Bacterial Infections: A PK/PD Approach.
Maguigan KL; Al-Shaer MH; Peloquin CA
Antibiotics (Basel); 2021 Sep; 10(10):. PubMed ID: 34680734
[TBL] [Abstract][Full Text] [Related]
13. Therapeutic drug monitoring of β-lactam antibiotics in the critically ill: direct measurement of unbound drug concentrations to achieve appropriate drug exposures.
Wong G; Briscoe S; McWhinney B; Ally M; Ungerer J; Lipman J; Roberts JA
J Antimicrob Chemother; 2018 Nov; 73(11):3087-3094. PubMed ID: 30137377
[TBL] [Abstract][Full Text] [Related]
14. Covariate determinants of effective dosing regimens for time-dependent beta-lactam antibiotics for critically ill patients.
Kaska M; Havel E; Selke-Krulichova I; Safranek P; Bezouska J; Martinkova J
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2018 Sep; 162(3):219-226. PubMed ID: 29582860
[TBL] [Abstract][Full Text] [Related]
15. Impact of β-lactam antibiotic therapeutic drug monitoring on dose adjustments in critically ill patients undergoing continuous renal replacement therapy.
Economou CJP; Wong G; McWhinney B; Ungerer JPJ; Lipman J; Roberts JA
Int J Antimicrob Agents; 2017 May; 49(5):589-594. PubMed ID: 28341612
[TBL] [Abstract][Full Text] [Related]
16. Therapeutic Drug Monitoring of Antifungal Agents in Critically Ill Patients: Is There a Need for Dose Optimisation?
Baracaldo-Santamaría D; Cala-Garcia JD; Medina-Rincón GJ; Rojas-Rodriguez LC; Calderon-Ospina CA
Antibiotics (Basel); 2022 May; 11(5):. PubMed ID: 35625289
[TBL] [Abstract][Full Text] [Related]
17. Effect of obesity on the pharmacokinetics of antimicrobials in critically ill patients: A structured review.
Alobaid AS; Hites M; Lipman J; Taccone FS; Roberts JA
Int J Antimicrob Agents; 2016 Apr; 47(4):259-68. PubMed ID: 26988339
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics and pharmacodynamics of beta-lactam antibiotics in critically ill patients.
Sulaiman H; Roberts JA; Abdul-Aziz MH
Farm Hosp; 2022 Mar; 46(3):182-190. PubMed ID: 36183212
[TBL] [Abstract][Full Text] [Related]
19. Beta-Lactam Dose Optimisation in the Intensive Care Unit: Targets, Therapeutic Drug Monitoring and Toxicity.
Legg A; Carmichael S; Chai MG; Roberts JA; Cotta MO
Antibiotics (Basel); 2023 May; 12(5):. PubMed ID: 37237773
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetic changes of antibiotic, antiviral, antituberculosis and antifungal agents during extracorporeal membrane oxygenation in critically ill adult patients.
Hahn J; Choi JH; Chang MJ
J Clin Pharm Ther; 2017 Dec; 42(6):661-671. PubMed ID: 28948652
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
